Kornimate/medical-research-clean huggingface dataset:
effects of up-cat with and without visual feedback in children with cp

Conditions: Cerebral Palsy

Summary: cerebral palsy (cp) is the most common neurological disorder of movement and/or posture and of motor function, which are due to a non-progressive interference or abnormality of the developing brain. in hemiplegic cerebral palsy (hcp), one side of the body is involved with the upper extremity more affected than the lower. hcp is treated by addressing the underlying cause and by various form of therapy to recover motor function. motor function in hemi paretic limb particularly fine motor skill may be improved by upper limb children action-observation therapy (up-cat).

this will be randomized controlled trial. non-probability purposive sampling technique will be used for recruiting samples for study. children will be assessed by house functional classification system for hemiplegia to include in the study. computerized randomization will be used to locate subjects in two groups, and 28 hemiplegic cerebral palsy children will be divided into 2 groups; experimental and control groups. in experimental group hemiplegic cerebral palsy children will perform upper limb exercises with visual feedback for 5 times a week, 15 sets of daily life upper limb activities, each action will be observed for 2 minutes and executed for 2 minutes. in control group hemiplegic cerebral palsy children will perform upper limb activities for 5 times a week, 15 sets of daily life upper limb activities, each action will be observed for 2 minutes and executed for 2 minutes. both groups will be assessed at the time of recruitment and at the end of 4 weeks. data will be collected by melbourne unilateral upper limb (muul) and abilhand-kids questionnaire. after collection of data, data will be analyzed by spss-25.

Eligibility criteria:
inclusion criteria: * cerebral palsy children aged 5 years to 10 years at the time of recruitment. * both male and female * according to modified ashworth scale of spasticity; score should be +1. * mild or moderate ul disability i.e. active use of affected ul from poor active assist use to complete spontaneous use according to house functional classification system grade between 4 and 8. exclusion criteria: * individuals with the other neurological deficits * visual impairment. * children with upper limb disabilities other than hemiplegic cerebral palsy. * children with uncontrolled epileptic seizures in last 3 years * non co-operative patients. * previous orthopedic surgery or botulinum toxin a (bont-a) injection in the ul within 6 months prior to the enrolment of this study.

Keywords: cerebral palsy (cp), rehabilitation upper extremity activities of daily living
comparison of loop and primary incision&drainage techniques in the emergency department

Conditions: Skin Abscess

Summary: skin abscesses are among the most common soft tissue infections cause emergency room visits frequently. management of abscess drainage and prevent further complications are important entities for emergency physicians. historically primary incision and drainage (i\&d) technique has found very effective method of abscess drainage, however a novel technique loop drainage holds promising. the purpose of our study is comparison efficacy of i\&d and loop drainage techniques in patients with cutaneous abscess.


Eligibility criteria:
inclusion criteria: * adult patients presenting to kocaeli university emergency department with cutaneous abscess. * providing written informed consent. exclusion criteria: * under 18 years of age. * immunosuppressive patients. * using medications have effects on wound healing. * abscess is not recognizable by bedside ultrasound. * lidocaine allergy
partner: panitumumab added to regimen for treatment of head and neck cancer evaluation of response

Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck

Summary: this is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with metastatic or recurrent head and neck cancer, as well as a cross-over second-line panitumumab monotherapy of subjects who fail the chemotherapy only arm. this study will be conducted in the united states. approximately 150 subjects with histologically or cytologically confirmed metastatic and/or recurrent scchn.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed metastatic and/or recurrent squamous cell carcinoma of head and neck (scchn) determined to be incurable by surgery and/or radiation therapy. * measurable disease by ct scan * eastern cooperative oncology group (ecog) performance score of 0 or 1 * age: 18 years or older * adequate hematologic, renal, metabolic, hepatic \& thyroid function exclusion criteria: * prior systemic treatment for metastatic and/or recurrent scchn * cns metastases, or nasopharyngeal carcinoma * history of interstitial lung disease * history of another primary cancer * any co-morbid disease that would increase risk of toxicity * active infection requiring systemic treatment * prior anti-epidermal growth factor receptor (anti-egfr) antibody therapy

Keywords: scchnc metastatic recurrent
clotild® smart guidewire system (csgs) evaluation in endovascular thrombectomy procedure

Conditions: Stroke

Summary: the purpose of this first-in-human study is to evaluate the safety of using the clotild® system to guide the endovascular thrombectomy (evt) device to the clot location during evt for the treatment of an acute ischemic stroke eligible to evt, whatever the evt device chosen. a secondary purpose is to assess the clinical performance, defined as the feasibility of measuring clot electrophysiological parameters in vivo during evt procedures.

clotild® is a neurovascular guidewire equipped with the sensome proprietary impedance sensor. the latter allows the measurement of the electrophysiological characteristics of the surrounding tissues. clotild® could categorize the thrombus occluding the cerebral blood vessel, and support the neurointerventionist during mechanical thrombectomy for the treatment of ischemic stroke. the aim of the study is to evaluate the safety and the performance of the device. the electrophysiological measurements will be used to update clotild®'s database and thus improve the prediction accuracy of the model in providing physicians with insights for mechanical thrombectomy.

Eligibility criteria:
inclusion criteria: 1. clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke eligible for evt 2. m1 and/or mca bifurcation arterial occlusion on computed tomography angiography (cta) or mra (magnetic resonance angiography) of an intracranial vessel amenable to evt 3. informed consent by subject, subject's legally authorized representative (lar) or anyone approved by the ethics committee (ec) and/or regulatory agencies to provide consent on behalf of the subject. exclusion criteria: 1. patient having an intracranial occlusion other than m1 and/or mca bifurcation, especially tandem occlusion and ica (internal carotid artery) occlusion. 2. current participation in another investigational device or drug study that has not completed the primary endpoint or that clinically interferes with the current study endpoints 3. candidates not eligible for evt based on neurointerventionist and/or neurologist investigators' opinion 4. pregnancy or lactating subjects
hcv viral hepatitis, blood sugar level and systolic blood pressure in egypt

Conditions: Hepatitis C, Acute; Diabetes; Hypertension

Summary: an observational double-blind cohort study that examined the association between hcv viral hepatitis, blood sugar level and systolic blood pressure in the egyptian population

a cohort study on greater than 70000 egyptian patients had been conducted. for all patients,1- we detected the hepatitis c virus (hcv) rna antigens ( hepatitis c virus)presence using bioline hcv kits( qualitative test for diagnosis of hepatitis c virus in the blood), for all positive patients, confirmatory rapid screening test was performed and all patients who tested positive twice underwent a qpcr test using qiaampminelute virus spin kit (thermo fisher scientific, waltham, ma, usa) performed according to the manufacturer's recommended protocol. 2- investigators measured blood sugar levels for each patient using accu-chek kits(finger stick sugar level measurement) 3- measured systolic blood pressure for each patient was measured using mercury meters. 4-for all patients investigators obtained full medical history regarding the presence or absence of chronic diabetes, chronic hypertension, coronary artery disease, kidney impairment with dialysis or chronic obstructive pulmonary disease. 5- for all patients investigators listed age, gender, and body mass index. 66121 patients were negative for hcv and 4852 were positive for hcv. investigators measured the association between hcv presence, high blood sugar levels and high systolic blood pressure. it is supposed that this is the largest study in the world that examined both associations. in a word, this study was responding to a specific question: is hepatitis c virus presence is associated with high blood pressure or high sugar level or both or not associated???

Eligibility criteria:
inclusion criteria * egyptian citizens from 18 years to 80 years. exclusion criteria: * patients younger than 18 years or older than 80 years
a trial to assess the pharmacokinetics, pharmacodynamics, and the safety and tolerability of semaglutide in healthy male japanese and caucasian subjects

Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy

Summary: this trial is conducted in asia. the aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), and the safety and tolerability of semaglutide in healthy male japanese and caucasian subjects.


Eligibility criteria:
inclusion criteria: * healthy male japanese and caucasian subjects * age between 20 and 55 years (both inclusive) at the time of signing informed consent * body weight of equal to or above 54.0 kg * body mass index (bmi) between 20.0 and 25.0 kg/m\^2 (both inclusive) * glycosylated haemoglobin a1c (hba1c) below or equal to 6.0% * for japanese subjects only: both parents japanese * for caucasian subjects only: both parents caucasian exclusion criteria: * any clinically significant disease history, in the opinion of the investigator, or systemic or organ disease including: cardiological, pulmonary, gastrointestinal, hepatic, neurologic, renal, genitourinary and endocrine, dermatologic or hematologic diseases * personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (men2) * history of chronic pancreatitis or idiopathic acute pancreatitis * calcitonin above or equal to 50 ng/l * history of alcohol abuse within 1 year from screening, or a positive result in the alcohol breath test, or consumption of more than 21 units of alcohol weekly: 1 unit of alcohol equals approximately 250 ml of beer or lager, or approximately120 ml (one glass) of wine or japanese sake, or approximately 20 ml of spirits * smoking of more than 5 cigarettes (including nicotine substitute products) or the equivalent, per day or unwilling to refrain from smoking whenever required for the trial procedure * use of prescription drugs within 3 weeks or 5 times the half-life, whichever is longer, prior to visit 2 (randomisation), non-prescription drugs within 1 week prior to visit 2 (randomisation). the use of vitamins, minerals and nutritional supplements, and the occasional use of paracetamol (acetaminophen) or acetylsalicylic acid are permitted
a study of trastuzumab emtansine (trastuzumab-mcc-dm1, t-dm1) in combination with pertuzumab administered to patients with human epidermal growth factor receptor-2 (her2)-positive locally advanced or metastatic breast cancer who have previously received trastuzumab

Conditions: Metastatic Breast Cancer

Summary: this was a multi-institutional, multinational, open-label, single-arm phase ib/ii study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of trastuzumab emtansine (trastuzumab-mcc-dm1) administered by intravenous (iv) infusion in combination with pertuzumab in patients with human epidermal growth factor receptor-2 (her2)-positive locally advanced or metastatic breast cancer who had previously received trastuzumab.

there were 2 phases in the study, a dose escalation phase (phase 1b) and a dose expansion phase (phase 2a). in the dose escalation phase, 3 patients were enrolled at the first dose level (3.0 mg/kg trastuzumab emtansine) and and 6 patients were enrolled at the second dose level (3.6 mg/kg trastuzumab emtansine). an additional 58 patients were enrolled at the 3.6 mg/kg trastuzumab emtansine dose level in the dose expansion phase (phase 2a) of the study.

Eligibility criteria:
inclusion criteria: * histologically documented human epidermal growth factor receptor 2 (her2)-positive locally advanced or metastatic breast cancer. * tumor tissue blocks or 15-20 unstained tissue slides for confirmatory central laboratory her2 status testing and other exploratory assessments. * prior trastuzumab in any line of therapy. * no prior trastuzumab emtansine (t-dm1) or pertuzumab therapy. * measurable disease. * for women of childbearing potential, agreement to use an effective form of contraception and to continue its use for the duration of the study. * life expectancy ≥ 90 days. exclusion criteria: * less than 21 days since the last anti-tumor therapy, including chemotherapy, biologic, experimental, immune, hormonal, or radiotherapy for the treatment of breast cancer, with the following exceptions: hormone-replacement therapy or oral contraceptives; palliative radiation therapy involving ≤ 25% of marrow-bearing bone if administered ≥ 14 days prior to first study treatment. * history of intolerance or hypersensitivity to trastuzumab and/or adverse events related to trastuzumab that resulted in trastuzumab being permanently discontinued. * peripheral neuropathy of grade ≥ 2. * history of clinically significant cardiac dysfunction. * current severe, uncontrolled systemic disease, eg, clinically significant cardiovascular, pulmonary, or metabolic disease. * brain metastases that are untreated, progressive, or have required any type of therapy to control symptoms from brain metastases within 60 days of the first study treatment. * history of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome.

Keywords: mbc breast cancer her2+ her2+ breast cancer her2 positive breast cancer herceptin trastuzumab emtansine
apneic oxygenation including precipitous intubations during rsi in the ed

Conditions: Apneic Oxygenation; Endotracheal Intubation

Summary: this rct is testing the efficacy of apneic oxygenation during endotracheal intubation in the emergency department. currently the standard practice in the ed when performing endotracheal intubation is that some providers use apneic oxygenation (the application of a nasal cannula at 15lpm) throughout the intubation procedure, while others do not apply apneic oxygenation. initial literature in the operating room showed that apneic oxygenation helps prevent desaturation during the procedure. however, the latest literature conducted in critical care settings (one study in the icu and one in the ed) questions the efficacy of this intervention in critically ill patients; however, no harm has been shown. our study aims to test this intervention further by adding in a special subset of patients that was excluded from prior studies, precipitous intubations, or those patients that have to be intubated quickly and cannot have adequate pre-oxygenation. we hypothesize that apneic oxygenation will be more efficacious in this subset than in the overall ed population. we will randomize patients requiring endotracheal intubation into intervention (apneic oxygenation) and control (no apneic oxygenation). we will measure the lowest arterial oxygen saturation from the start of the intubation procedure through 2 minutes after intubation is complete.


Eligibility criteria:
inclusion criteria: * the inclusion criteria for our study will include patients 18 years or older who require emergent endotracheal intubation utilizing rapid sequence intubation (rsi) in the emergency department with first attempt taken by a resident or attending physician working in the emergency department. this includes emergency medicine attending physicians and residents as well as non-emergency medicine rotators (e.g.., internal medicine residents who are rotating through the emergency department). exclusion criteria: * exclusion criteria include patients who are in cardiac arrest, or if the patient received any positive pressure ventilation (i.e, bpap, cpap, bvm) in the emergency department before rsi.

Keywords: apneic oxygenation endotracheal intubation airway management emergency department
tap block with liposomal bupivacaine versus bupivacaine in robotic hysterectomy

Conditions: Acute Pain

Summary: the purpose of the study is to compare pain control after robotic hysterectomy surgery using either liposomal bupivacaine or bupivacaine when injected during a transversus abdominis plane (tap) block. robotic hysterectomy is when a patient is electively having robotic assisted removal of one's uterus. both medications liposomal bupivacaine and bupivacaine are standard of care in these types of surgeries.

treatment technique: the patient will be in the supine position. the transversus abdominis muscle layer will be identified with the ultrasound. using sterile technique, skin infiltration with 2% lidocaine will occur, 2 cm medial to the ultrasound probe. an 22g nerve block needle will then be inserted and advanced under ultrasound guidance until it is below the fascial covering of the transversus abdominis muscle layer. gentle aspiration for air, or blood will be performed and either 30 cc of 0.25% bupivacaine with 1/200,000 parts epinephrine or 30 ml of liposomal bupivacaine mixed 1:1 with normal saline will be injected under ultrasound guidance. for each 5cc of local anesthetic injected, aspiration will be performed. upon completion of the injection, the needle will then be removed. this will then be completed on the contralateral side. the patient will be monitored in the preoperative area until he/she is brought into the operating room for their procedure. when the operation is complete the patient will either be discharged home or brought to the ward where each day a member of the research team will evaluate the patient for signs of complications and ask the patient their minimum and maximum pain score. if patients have met criterion for discharge to home including pain \<4/10, independence of intravenous analgesia, and are stable for discharge medically, but are awaiting placement, the time of discharge for the purposes of the study will be the day they have met such criterion as opposed to the day of actual discharge, as this can vary depending on patient placement. if the patient is discharged prior to 72 hours post injection, then the patient will receive one phone call at 24 hours post injection, 48 hours post injection , and 72 hours post injection +/- 5 hours. during this phone call the patient will be asked about pain score, narcotic use, overall satisfaction via a recorded patient questionnaire, quality of recovery via a quality of recovery survey, and assessed if any adverse events have occurred. adequate analgesia will be defined as \<3 vas at rest, and if vas is greater than 3 adjustments in oral or intravenous pain medications will be given as determined by the nurse.

Eligibility criteria:
inclusion criteria: * those who present for elective robotic assisted hysterectomy exclusion criteria: * non english speaking * chronic pain * on opioids greater than 1 weeks * chronic anticoagulation * allergy to local anesthetics * use of spinal or epidural for surgery * lack of patient cooperation * contraindication to regional anesthesia
effect of estradiol+drospirenone versus estradiol+mpa on endothelial function

Conditions: Cardiovascular Diseases

Summary: this study compares the effects of two common hormone medications on the heart and blood vessels of healthy post-menopausal women over the age of 45. the study will take place over the course of about 5 months. each subject will take two different medications over two six-week periods. they will be randomized at the beginning of the study to either estradiol+medroxyprogesterone acetate or estradiol+drospirenone for the first period, and will receive the other medication the second six-weeks of the study. at the very beginning of the study and at the end of each six-week treatment period, subjects will come to the hospital various tests including non-invasive blood vessel imaging tests, blood draws to test the levels of certain hormones in the body, an oral glucose tolerance test, a test to monitor renal blood flow, and 24-hour blood pressure monitoring. between treatment periods, there will be a four-week medication-free washout period.


Eligibility criteria:
inclusion criteria: 1. healthy female postmenopausal volunteers, as defined by absence of menses for at least 12 months and follicle stimulating hormone (fsh) 30 iu/l; 2. age 45 to 75 years; 3. systolic blood pressure \ 90 mmhg and diastolic blood pressure \ 60 mmhg at the screening visit; 4. no personal history of diabetes; 5. body mass index \< 30 kg/m2; 6. no clinically significant abnormalities on screening tests (complete blood count, serum electrolytes, liver enzymes, thyroid stimulating hormone, urinalysis, and electrocardiogram). exclusion criteria: 1. current smoking, defined as smoking within the 12 months before the screening visit; 2. alcohol intake \>1 beverage per night or history of alcohol abuse; 3. current or past recreational drug use; 4. personal history of hypertension, cardiovascular disease (coronary artery disease, congestive heart failure, valvular heart disease, stroke, transient ischemic attack, or intermittent claudication), hyperlipidemia, diabetes (defined as a fasting glucose ≥126 mg/dl), kidney disease, liver disease, venous or arterial thromboembolic disease, adrenal insufficiency, depression, or illness requiring overnight hospitalization in the past 6 months; 5. risk factors for arterial or venous thromboembolism; 6. personal history of breast cancer or any other type of cancer; 7. personal history of endometrial hyperplasia, endometrial cancer, or unexplained vaginal bleeding; 8. history of cervical cancer or abnormal pap smear 9. prescription or herbal medication use, excluding thyroid hormone supplementation; 10. ischemic changes on resting electrocardiogram; 11. serum creatinine ≥ 1.3 mg/dl. 12. serum potassium level \> 5.0 mmol/l; 13. known hypersensitivity to any of the study drugs; 14. other active medical problems detected by examination or laboratory testing, except for treated hypothyroidism. 15. pregnancy

Keywords: cardiovascular, vascular